Work

First-in-human phase I study of HSK41959, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP -deleted advanced solid tumors.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e15097

Authors: Fei Zhou, Caicun Zhou, Chuangzhou Rao, Tongsen Zheng, Haipeng Xu, Jie Liu, Yongsheng Wang, Runxiang Yang, Chao Yu

Institutions: Tongji University, Shanghai East Hospital, Ningbo No. 2 Hospital, Third Affiliated Hospital of Harbin Medical University, Fujian Provincial Cancer Hospital, Henan Cancer Hospital, Nanjing Drum Tower Hospital, Affiliated Hospital of Guizhou Medical University

Language: English

Topic: Cancer-related gene regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Haisco Pharmaceutical Group

OpenAlex ID: W7162690812

Cites:

Cited by:

Related to: